Equity Research Biotechnology

Should You Buy DBV Technologies S.A. Stock in 2026?

By CirclFi Research Team · · Updated · 0/13 models active

According to the CirclFi Deep Alpha Valuation Engine, DBV Technologies S.A. (DBVT) scores 5.4/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $11.76, our multi-model valuation analyzes whether the market has already discounted these weaknesses.

The short answer: 0 of 0 CirclFi valuation models project upside for DBV Technologies S.A. (DBVT) at $11.76 — the models are evenly split, with a Quality Score of 5.4/10 and Value-Trap risk of 57/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • Models are split: 0 bullish vs 0 bearish
  • Quality Score: 5.4/10 — Moderate — mixed signals
  • Value Trap Risk: 57/100 — Elevated — exercise caution
  • Fair Value Range: — – —

Bullish Models

0 / 0

Bearish Models

0 / 0

Quality Score

5.4 /10

Moderate — mixed signals

Value Trap Risk

57 /100
Elevated

Elevated — exercise caution

Model Consensus

0 /13
Active Models

Full institutional coverage

What Is the Investment Case for DBV Technologies S.A. (DBVT) in 2026?

What Is the Bull Case vs the Bear Case for DBV Technologies S.A. (DBVT)?

Bull case versus bear case for DBV Technologies S.A. (DBVT) at $11.76, derived from 0 active CirclFi valuation models on 2026-09-15.
Bull case Bear case
No active model projects meaningful upside for DBVT at $11.76. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. No active model flags significant downside for DBVT. The Value Trap score of 57/100 still argues for some caution.

How Does DBVT Compare to Its Biotechnology Peers?

VRCA Verrica Pharmaceutic
5.4
GOSS Gossamer Bio, Inc.
5.4
CAPR Capricor Therapeutic
5.4
HYFT MindWalk Holdings Co
5.4
CNTB Connect Biopharma Ho
5.4
RVMD Revolution Medicines
5.4
RLMD Relmada Therapeutics
4.8
CVM CEL-SCI Corporation
3.9

Valuation data pages: VRCA · GOSS · CAPR · HYFT · CNTB · RVMD · RLMD · CVM · MDGL · EXEL · INCY

See full Biotechnology rankings →

Which Other Stocks Score Like DBVT on Quality?

Closest companies to DBVT’s Quality of Company score of 5.4/10, across all industries.

Why Do CirclFi’s 0 Models Disagree on DBVT?

What Are the Biggest Risks of Buying DBVT Stock?

Value Trap Warning

VT score 57/100 — apparent discount may mask decay.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View DBVT Data Page →

So Is DBV Technologies S.A. (DBVT) Worth Buying in 2026?

DBV Technologies S.A. currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.

These are quantitative model outputs, not investment recommendations. DBV Technologies S.A.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About DBVT Stock?

Should I buy DBVT stock right now?

Based on CirclFi's multi-model analysis, 0 of 0 models see upside for DBVT at $11.76. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in DBV Technologies S.A.?

Key risks include: an elevated Value Trap score of 57/100, suggesting apparent undervaluation may mask deteriorating fundamentals; limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does DBVT compare to its competitors?

Among Biotechnology peers, DBVT holds a Quality Score of 5.4/10. Comparable companies include VRCA (QOC 5.4), GOSS (QOC 5.4), CAPR (QOC 5.4). The relative ranking helps investors identify whether DBVT offers better fundamental quality than alternatives in the same sector.

Is DBVT a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. DBVT's Quality Score of 5.4/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy DBVT at?

CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for DBVT.

View DBVT Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →